BLS FY2027 Guidance

Aug 30, 2026 at 10:51 PM EDT · Issued by BLS Pharmaceuticals Limited via ASX

Filed with ASX · Aug 30, 2026 at 10:51 PM EDT

On 6ix: 6ix.com/news/bls-fy2027-guidance

Suite 506, Level 5 50 Clarence Street, Sydney NSW 2000, Australia hello@breathelifesciences.com +61 2 9078 8180 BLS Pharmaceuticals Ltd | ASX:BLS | www.blspharma.com 1 31 August 2026 BLS targets $105 - $115 million revenue in FY2027 FY2027 Full Year...

View Attachment

6ix hasn’t read this filing yet.

BLS Pharmaceuticals Limited on 6ix

In the deck

BLS Pharmaceuticals — Investor Presentation (August 2026)24 slidesAug 31, 2026

Earlier from BLS Pharmaceuticals

BLS Investor PresentationAug 30
BLS FY2026 Results AnnouncementAug 30
Annual Report to shareholdersAug 30
BLS FY2026 Results Webinar 2 September 2026 8am AESTAug 26
Application for quotation of securities - BLSAug 12

Later from BLS Pharmaceuticals

Appendix 4G Corporate Governance StatementAug 31
S&P DJI Announces September 2026 Quarterly RebalanceSep 4
Angus Walker Appointed Alternate Director to Edward MyerSep 13
Initial Director's Interest NoticeSep 14
AGM Date and Director NominationsOct 6

All BLS Pharmaceuticals news releases

Follow BLS Pharmaceuticals into a list and get an email when it puts out news.

Follow BLS Pharmaceuticals